(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...
Singapore sovereign wealth fund Temasek plans to deploy another $10 billion in India over the next 2 to 3 years, focusing on ...
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient ...
The Million Dollar Sellers group convened last week in New York City during and around Amazon’s own Seller Growth Summit ...
"If you are at all concerned... visit your local doctor or GP." ...
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer ...
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer ...
Cellares secures new funding, partnerships and FDA recognition as it prepares for commercial-scale cell therapy manufacturing ...
Capital markets regulator Securities and Exchange Board of India (SEBI) on Friday cautioned listed companies and regulated ...
The selective D1/D5 agonist significantly improved Parkinson’s disease motor symptoms, with low rates of somnolence and ...
Operation Brock, the traffic management scheme that diverts lorries heading to the Dover and Folkestone ports to the M20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results